相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。
Article
Infectious Diseases
Arvind Gharbharan et al.
Summary: This study aimed to determine the effectiveness of convalescent plasma therapy in high-risk outpatients with COVID-19. The results showed that convalescent plasma therapy did not improve the disease severity score.
CLINICAL MICROBIOLOGY AND INFECTION
(2023)
Article
Oncology
Thomas Hueso et al.
Summary: Patients with hematological malignancy and COVID-19 have a high mortality rate. COVID-19 convalescent plasma (CCP) therapy shows promise in transferring neutralizing antibodies to enhance the immune response. In patients with B-cell lymphoid disease who have received anti-CD20 therapy, CCP treatment is associated with a lower mortality rate.
Article
Multidisciplinary Sciences
Yogiraj Ray et al.
Summary: A clinical trial was conducted involving 80 severe COVID-19 patients to assess the effectiveness of convalescent plasma therapy (CPT). The results showed that CPT did not affect mortality rate in severe COVID-19 patients, and there were no significant clinical benefits observed.
NATURE COMMUNICATIONS
(2022)
Article
Medicine, General & Internal
Mila B. Ortigoza et al.
Summary: The randomized clinical trial did not show significant benefits of COVID-19 convalescent plasma (CCP) in hospitalized patients compared to placebo. However, exploratory analyses suggested that high-titer CCP may have benefits for early participants in the pandemic when other treatments were not in use. This indicates a heterogeneous treatment effect of CCP over time.
JAMA INTERNAL MEDICINE
(2022)
Article
Hematology
Petra Langerbeins et al.
Article
Respiratory System
Leo Sekine et al.
Summary: This study investigated the effect of convalescent plasma therapy in hospitalized COVID-19 patients. The results showed that convalescent plasma therapy did not result in a higher proportion of clinical improvement compared to standard of care alone.
EUROPEAN RESPIRATORY JOURNAL
(2022)
Article
Medicine, General & Internal
D. J. Sullivan et al.
Summary: This study evaluated the efficacy and safety of COVID-19 convalescent plasma in symptomatic adults and found that receiving convalescent plasma transfusion reduced the risk of hospitalization due to COVID-19-related reasons.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Review
Medicine, General & Internal
Emma Khoury et al.
Summary: The study found that patients with cancer and SARS-CoV-2 infection had a higher risk of death compared to those without cancer. Younger age, lung cancer, and hematologic cancer were identified as risk factors associated with poor outcomes from COVID-19.
Article
Medicine, General & Internal
Lise J. Estcourt et al.
Summary: This article introduces the therapeutic application of convalescent plasma for COVID-19 patients and provides corresponding clinical practice guidelines. The guidelines include recommendations for the use of convalescent plasma for outpatients and inpatients, as well as for prophylactic application. For high-risk patients, it is recommended to transfuse convalescent plasma in addition to standard care, while for hospitalized patients without detectable SARS-CoV-2 antibodies, it is suggested to transfuse convalescent plasma in addition to standard care.
ANNALS OF INTERNAL MEDICINE
(2022)
Article
Oncology
Francesco Lanza et al.
Summary: This retrospective study assessed the clinical outcome of COVID-19 in patients with hematological malignancies treated with anti-SARS-CoV-2 convalescent plasma or standard of care therapy. The results indicated a lack of efficacy of convalescent plasma in this high-risk patient cohort, consistent with previous randomized studies in immunocompetent individuals with COVID-19.
HEMATOLOGICAL ONCOLOGY
(2022)
Review
Immunology
Susan DeWolf et al.
Summary: Immunocompromised individuals, especially those with hematologic malignancies, are at higher risk of SARS-CoV-2-related diseases and death due to immune deficiencies. Understanding the progression of viral infections in these individuals is crucial and can help improve prevention and treatment strategies for COVID-19.
Article
Multidisciplinary Sciences
David J. Sullivan et al.
Summary: The study suggests that convalescent plasma has a high neutralizing effect against the Omicron variant, while vaccinated individuals also show good neutralizing effects. These findings have implications for both previous CCP stocks and future plans to restart CCP collections.
NATURE COMMUNICATIONS
(2022)
Article
Medicine, Research & Experimental
Sixten Koerper et al.
Summary: Results from an extended observation of a randomized trial on COVID-19 convalescent plasma treatment showed a trend towards better outcomes in the CCP group compared to the control group, with significantly improved long-term survival seen in patients receiving higher levels of neutralizing antibodies. The study also found no significant difference in the increase of neutralizing antibodies after vaccination between the two groups.
JOURNAL OF CLINICAL INVESTIGATION
(2022)
Article
Multidisciplinary Sciences
Meenu Bajpai et al.
Summary: This study compared the efficacy and safety of COPLA and FFP in treating severe COVID-19 patients. The results showed that there was no significant difference in the proportion of patients free of ventilation at day seven between the COPLA group and the control group. However, improvements in respiratory rate, O2 saturation, SOFA score, and Ct value were observed in the COPLA group. No serious adverse events were noticed in both groups after plasma transfusion.
ANAIS DA ACADEMIA BRASILEIRA DE CIENCIAS
(2022)
Article
Medicine, Research & Experimental
Maddalena Marconato et al.
Summary: This study provides preliminary evidence that treatment with convalescent plasma therapy, particularly with highly neutralizing plasma, is associated with faster clearance of the SARS-CoV-2 virus in hospitalized COVID-19 patients.
JOURNAL OF CLINICAL INVESTIGATION
(2022)
Article
Multidisciplinary Sciences
Pere Millat-Martinez et al.
Summary: This study assessed whether convalescent plasma (CP) administered during the first week of symptoms reduced disease progression or risk of hospitalization in COVID-19 outpatients. The results showed that CP had no significant impact on disease severity scale and hospitalization or death, but may have some effect in patients with symptoms lasting <= 5 days. Additionally, CP did not shorten the time to full symptom resolution.
NATURE COMMUNICATIONS
(2022)
Article
Respiratory System
Timothy Devos et al.
Summary: Transfusion of 4 units of convalescent plasma with high neutralising antibody titres early in hospitalised COVID-19 patients did not result in a significant improvement of clinical status or reduced mortality.
EUROPEAN RESPIRATORY JOURNAL
(2022)
Article
Immunology
Gil C. De Santis et al.
Summary: A multicenter randomized trial in Brazil showed that high-dose convalescent plasma transfusion within 10 days of symptom onset did not benefit patients with severe COVID-19.
EMERGING INFECTIOUS DISEASES
(2022)
Article
Respiratory System
Bruce Kirenga et al.
Summary: In this trial in Uganda, convalescent plasma therapy did not lead to beneficial virological or clinical improvements. Further trials are needed to determine subgroups of patients who may benefit from convalescent plasma in Africa.
BMJ OPEN RESPIRATORY RESEARCH
(2021)
Article
Medicine, General & Internal
R. Libster et al.
Summary: A randomized, double-blind, placebo-controlled trial of convalescent plasma with high IgG titers against SARS-CoV-2 in older adult patients within 72 hours after the onset of mild Covid-19 symptoms found that early administration of high-titer convalescent plasma reduced the progression of Covid-19 in mildly ill infected older adults.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
M. J. Joyner et al.
Summary: This study found that higher anti-SARS-CoV-2 IgG antibody levels in convalescent plasma were associated with a lower risk of death among patients hospitalized with Covid-19 who were not receiving mechanical ventilation. The association between antibody levels and mortality risk was moderated by mechanical ventilation status, with no significant effect seen in patients who had already received ventilation.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
V. A. Simonovich et al.
Summary: There were no significant differences observed in clinical status or overall mortality between patients treated with convalescent plasma and those who received placebo in the treatment of severe Covid-19 pneumonia. The study results indicate that both groups had similar clinical outcomes and mortality rates after 30 days.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
Lise J. Estcourt et al.
Summary: Among critically ill adults with confirmed COVID-19, treatment with 2 units of high-titer, ABO-compatible convalescent plasma had a low likelihood of providing improvement in the number of organ support-free days.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2021)
Article
Medicine, General & Internal
Maria Elvira Balcells et al.
Summary: The study did not find evidence of benefit in mortality, length of hospitalization, or mechanical ventilation requirement by immediate addition of CP therapy in the early stages of COVID-19 compared to its use only in case of patient deterioration.
Article
Medicine, General & Internal
Francesco Menichetti et al.
Summary: The clinical trial comparing convalescent plasma (CP) plus standard therapy (ST) with ST alone in hospitalized patients with COVID-19 pneumonia showed that high-titer anti-SARS-CoV-2 CP did not reduce the progression to severe respiratory failure or death within 30 days.
Article
Multidisciplinary Sciences
Manaf AlQahtani et al.
Summary: The pilot study suggests that CP therapy is safe in hospitalized COVID-19 patients, but there were no significant differences in primary and secondary outcome measures compared to standard therapy. A larger definitive study is needed for confirmation.
SCIENTIFIC REPORTS
(2021)
Article
Biology
Karin Holm et al.
Summary: The study aimed to investigate the efficacy of convalescent plasma in hospitalized COVID-19 patients, but no significant differences were observed between the convalescent plasma group and standard of care group.
BMC RESEARCH NOTES
(2021)
Article
Biochemistry & Molecular Biology
Philippe Begin et al.
Summary: Convalescent plasma did not reduce the risk of intubation or death at 30 days in hospitalized patients with COVID-19. Transfusion of convalescent plasma with unfavorable antibody profiles could be associated with worse clinical outcomes compared to standard care.
Article
Medicine, General & Internal
Frederick K. Korley et al.
Summary: This study showed that administering Covid-19 convalescent plasma to high-risk outpatients within 1 week after symptom onset did not prevent disease progression.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Multidisciplinary Sciences
Arvind Gharbharan et al.
Summary: A clinical trial on 86 COVID-19 patients treated with convalescent plasma showed no overall clinical benefit, as most patients already had potent antibodies upon admission, leading to the trial being terminated prematurely.
NATURE COMMUNICATIONS
(2021)
Article
Oncology
Michael A. Thompson et al.
Summary: This study evaluated the association of convalescent plasma treatment with 30-day mortality in hospitalized adults with hematologic cancers and COVID-19. Results showed that convalescent plasma treatment was associated with improved 30-day mortality, especially in patients requiring intensive care unit admission or mechanical ventilatory support.
Article
Immunology
Hector Rincon-Arevalo et al.
Summary: Patients with kidney failure are at increased risk for SARS-CoV-2 infection, making effective vaccination critical. However, studies have found significantly impaired antibody responses to the BNT162b2 vaccine in kidney transplant recipients and dialysis patients, leading to insufficient immune responses.
SCIENCE IMMUNOLOGY
(2021)
Article
Multidisciplinary Sciences
Paola de Candia et al.
Summary: The study results indicate that the use of convalescent plasma in early stages of COVID-19 can significantly reduce mortality, but its effectiveness is not significant in severe or critical conditions. Additionally, plasma with high antibody titers does not increase the benefit in reducing mortality.
Article
Medicine, Research & Experimental
Katharine J. Bar et al.
Summary: This study assessed the efficacy of CCP in severely ill, hospitalized adults with COVID-19 pneumonia, showing significant benefits in clinical severity score and 28-day mortality. The results suggest that CCP may benefit select populations, especially those with comorbidities who are treated early.
JOURNAL OF CLINICAL INVESTIGATION
(2021)
Article
Medicine, Research & Experimental
Cristina Avendano-Sola et al.
Summary: The study conducted in Spain involving 27 hospitals showed that convalescent plasma (CP) can significantly reduce the risk of progression to invasive mechanical ventilation or ECMO treatment, or death within 28 days for COVID-19 patients. However, the difference was not significant at 14 days and there was no significant improvement in overall survival.
JOURNAL OF CLINICAL INVESTIGATION
(2021)
Article
Medicine, Research & Experimental
Max R. O'Donnell et al.
Summary: This study found that the use of convalescent plasma was not associated with significant improvement in the clinical status at day 28 for severe COVID-19 patients, but it was related to significantly improved survival rates.
JOURNAL OF CLINICAL INVESTIGATION
(2021)
News Item
Medicine, General & Internal
Rita Rubin
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2020)
Article
Pathology
Eric Salazar et al.
AMERICAN JOURNAL OF PATHOLOGY
(2020)
Letter
Hematology
Vallari Shah et al.
BRITISH JOURNAL OF HAEMATOLOGY
(2020)
Article
Infectious Diseases
J. C. Marshall et al.
LANCET INFECTIOUS DISEASES
(2020)
Article
Medicine, General & Internal
Anup Agarwal et al.
BMJ-BRITISH MEDICAL JOURNAL
(2020)
Letter
Medicine, General & Internal
Teresa Aydillo et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2020)
Article
Mathematical & Computational Biology
Cyrus R. Mehta et al.
STATISTICS IN MEDICINE
(2011)
Article
Mathematical & Computational Biology
YHJ Chen et al.
STATISTICS IN MEDICINE
(2004)
